These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15497908)

  • 1. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens.
    Schürmann R; Holler T; Benda N
    Climacteric; 2004 Jun; 7(2):189-96. PubMed ID: 15497908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
    Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
    Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes.
    Gerlinger C; Gude K; Schmelter T; Schaefers M; Endrikat J
    Climacteric; 2015; 18(4):512-7. PubMed ID: 26000627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
    Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
    Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptoms.
    Sutter G; Schmelter T; Gude K; Schaefers M; Gerlinger C; Archer DF
    Menopause; 2014 Mar; 21(3):236-42. PubMed ID: 23963309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
    Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
    Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study.
    Paoletti AM; Cagnacci A; Di Carlo C; Orrù MM; Neri M; D'Alterio MN; Melis GB
    Gynecol Endocrinol; 2015 May; 31(5):384-7. PubMed ID: 25703254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
    Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
    Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
    Simon JA;
    Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women.
    Rozenbaum H; Chevallier O; Moyal M; Durand G; Perineau M; This P;
    Climacteric; 2002 Sep; 5(3):249-58. PubMed ID: 12419083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial.
    Buster JE; Koltun WD; Pascual ML; Day WW; Peterson C
    Obstet Gynecol; 2008 Jun; 111(6):1343-51. PubMed ID: 18515518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women.
    Chaikittisilpa S; Angsuwathana S; Chaovisitsaree S; Jirapinyo M; Wilawan K; Panyakhamlerd K; Jaisamrarn U; Techatraisak K; Morakote N; Suchartwatnachai C; Kongmephol W; Taechakraichana N
    J Med Assoc Thai; 2011 Sep; 94(9):1019-25. PubMed ID: 21970189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group.
    Rovati LC; Setnikar I; Genazzani AR
    Gynecol Endocrinol; 2000 Aug; 14(4):282-91. PubMed ID: 11075300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms.
    Al-Azzawi F; Buckler HM;
    Climacteric; 2003 Jun; 6(2):118-27. PubMed ID: 12841882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
    Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
    Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
    Genazzani AR; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Climacteric; 2013 Aug; 16(4):490-8. PubMed ID: 23531117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
    Buckler H; Al-Azzawi F;
    BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.